이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

T1D-CATCH Protocol: Collaboration Around Technology Using Community Health Workers for Young Adults With Type 1 Diabetes (T1D-CATCH)

2026년 10월 20일 업데이트: Albert Einstein College of Medicine

The objective of this study is to test the early effects and implementation of an enhanced community health worker (CHW) model (T1D-CATCH) that encourages and supports diabetes technology use in young adults from underrepresented minority groups (YA-URMs) with type 1 diabetes (T1D). The investigators will conduct a 9-month randomized controlled trial in which YA-URMs will be randomized to T1D-CATCH or usual care. The investigators will recruit from adult and pediatric endocrinology and primary care practices in a large safety-net health system in the Bronx, New York. Our specific aims are to 1) evaluate T1D-CATCH effects on technology initiation and continued use over 6 months and 2) evaluate T1D-CATCH implementation using Proctor's Taxonomy of Implementation Outcomes: feasibility, adoption, fidelity, and cost.

연구 개요

상세 설명

The study will involve a 9-month randomized control trial of usual care versus T1D-CATCH, an intervention that enhances core community health worker (CHW) service roles to support increased use of T1D technology in young adults (underrepresented minorities) (YA-URM's). Participants will be recruited from primary and specialty care practices at Montefiore Medical Center in the Bronx, New York, which is a large safety-net hospital system in one of the poorest counties in the U.S. Two young adult-aged CHWs from the Montefiore CHW program will be trained extensively per our Supporting Emerging Adults with Diabetes (SEAD) program manuals. For YA-URMs, CHWs will conduct hands-on diabetes technology education, goal-setting, peer support, and social service linkage. CHWs will also help shift insurance approval tasks away from busy providers and better align patient-provider priorities through close communication between the YA-URM and provider. Group sessions will be optional and will follow the YA-centric education curriculum developed in Dr. Agarwal's Supporting Emerging Adults with Diabetes (SEAD) program.

연구 유형

중재적

등록 (실제)

119

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • New York
      • The Bronx, New York, 미국, 10461
        • Albert Einstein College of Medicine

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • T1D duration ≥6 months
  • 18-35 years old
  • Self-identified URM status: non-Hispanic Black or Hispanic
  • English- or Spanish-speaking
  • Not currently on a connected diabetes technology system (includes never offered, prescribed but not started within 3 months of receiving the device, discontinued, or previously refused technology)

Exclusion Criteria:

  • Developmental or sensory disability interfering with study participation
  • Current pregnancy
  • Participation in another behavioral or diabetes technology intervention study in the past 6 months.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 건강 서비스 연구
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 더블

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: T1D-CATCH

The CHW intervention will consist of both individual and optional group sessions with YA-URMs with T1D. In individual sessions, CHWs will provide T1D technology education, peer support, and social needs management. Over the 9-month study period, session frequency will involve weekly individual sessions based on participant technology milestones and an optional monthly CHW-led peer group support session. CHW individual and group sessions will be held via videoconferencing or in person, per participant preference and institutional COVID-19 rules.

As defined by the Centers for Disease Control and Prevention (CDC), a CHW is "a frontline public health worker who is a trusted member of a community or who has a thorough understanding of the community being served, and leverages this unique position to link health systems, social services, and communities". CHWs engender trust with patients by having direct community and lived experience, offering specific support and empathy that may be difficult for other diabetes care professionals to provide. In addition, CHWs have firsthand understanding of cultural barriers to traditional western healthcare and can promote patient-centered culturally-relevant care. They enhance team-based care by helping providers with extra outreach, social needs management, time-consuming tasks, and aligning patient-provider priorities.

CHWs in this project will provide social needs assessment and management, introduction to diabetes technologies, and support for onboarding to technology.

간섭 없음: Usual Care Control Condition

Control arm participants will receive usual primary or endocrine care at Montefiore. Usual care consists of a physician or nurse practitioner visit with review of blood sugars and treatment decisions based on provider experience. Physicians in endocrinology practices are nested within a diabetes center with access to diabetes nurse practitioners/educators, dieticians, a psychologist, and nurses. In all practices, patients are recommended to see their physician or nurse practitioner every 3 months and attend individual or group sessions.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Technology Initiation
기간: Up to 6 months after initiating intervention

Technology initiation will be assessed by the percentage of participants initiating diabetes technology and will be reported as a binary variable (yes/no). Technology will include any combination of continuous glucose monitor (CGM), insulin pump, or CGM and insulin pump. Technology initiation will be defined as at least 1 week of first use during the 6-month period following intervention. Data will be ascertained from electronic medical record (EMR) prescriptions, participant self-reporting, CHW dashboard, and device platform data. Variables will be summarized by study group using summary statistics with counts/percentages.

Up to 6 months after initiating intervention

2차 결과 측정

결과 측정
측정값 설명
기간
Technology Initiation
기간: Up to 3 months after initiating intervention

Technology initiation will be assessed by the percentage of participants initiating diabetes technology and will be reported as a binary variable (yes/no). Technology will include any combination of continuous glucose monitor (CGM), insulin pump, or CGM and insulin pump. Technology initiation will be defined as at least 1 week of first use during the 3-month period following intervention. Data will be ascertained from electronic medical record (EMR) prescriptions, participant self-reporting, CHW dashboard, and device platform data. Variables will be summarized by study group using summary statistics with counts/percentages.

Up to 3 months after initiating intervention
Continued Technology Use - Percent Use
기간: 9 months following intervention

Continued technology use by study end will be determined from device platform metrics detailing days/percent time used, in addition to self-report. Per standard diabetes technology clinical trial guidelines, CGM use is defined as pump use >90% time. The percentage of time used (% used) will be summarized by study arm using basic descriptive statistics. A target of at least 90% CGM wear-time is associated with the best outcomes for glycemic control.

9 months following intervention
Continued Technology Use - Days of Wear
기간: 9 months following intervention

Continued technology use by study end will be determined from device platform metrics detailing days/percent time used, in addition to self-report. Per standard diabetes technology clinical trial guidelines, CGM use is defined as ≥ 5/7 days wear over the 9 month period. Days of wear will be summarized study arm using basic descriptive statistics. A target of at least 5/7 days of CGM wear-time is associated with the best outcomes for glycemic control.

9 months following intervention

기타 결과 측정

결과 측정
측정값 설명
기간
Feasibility Check
기간: 6 months (post-intervention)

Post-intervention interviews examining intervention content, complexity, comfort, delivery, and credibility

6 months (post-intervention)
Adoption
기간: 9 months (post-intervention)

Measured by recruitment logs

9 months (post-intervention)
Adoption
기간: 9 months (post-intervention)

Measured by electronic medical records (EMR)

9 months (post-intervention)
Adoption
기간: 9 months (post-intervention)

Measured by young adult participant consent rates

9 months (post-intervention)
Adoption
기간: 9 months (post-intervention)

Measured by percentage of provider opt-in

9 months (post-intervention)
Adoption
기간: 9 months (post-intervention)

Measured by CHW communications

9 months (post-intervention)
Fidelity
기간: Baseline

Measured by the community health worker (CHW) dashboard

Baseline
Fidelity
기간: Baseline

Measured by electronic medical records (EMR) to analyze session attendance

Baseline
Fidelity
기간: Baseline

Measured by content delivery

Baseline
Fidelity
기간: 3 month mark

Measured by community health workers (CHW) dashboard

3 month mark
Fidelity
기간: 3 month mark

Measured by CHW session recordings

3 month mark
Fidelity
기간: 3 month mark

Measured by EMR to analyze session attendance

3 month mark
Fidelity
기간: 3 month mark

Measured by content delivery

3 month mark
Fidelity
기간: 3 month mark

Measured by insurance tasks

3 month mark
Fidelity
기간: 6 month mark

Measured by CHW dashboard

6 month mark
Fidelity
기간: 6 month mark

Measured by CHW session recordings

6 month mark
Fidelity
기간: 6 month mark

Measured by EMR to analyze session attendance

6 month mark
Fidelity
기간: 6 month mark

Measured by content delivery

6 month mark
Fidelity
기간: 6 month mark

Measured by insurance tasks

6 month mark
Cost
기간: 6 months (post-intervention)

Measured by time sheets, receipts, and budget to analyze CHW salary/benefits

6 months (post-intervention)
Cost
기간: 6 months (post-intervention)

Measured by time sheets, receipts, and budget to analyze CHW equipment

6 months (post-intervention)
Cost
기간: 6 months (post-intervention)

Measured by time sheets, receipts, and budget to analyze CHW consumables

6 months (post-intervention)
YA-URM Autonomy/ Competence, Social Support
기간: Baseline

Measured using the Healthcare Self-Determination survey

Baseline
YA-URM Autonomy/ Competence, Social Support
기간: 3 month mark

Measured using the Healthcare Self-Determination survey

3 month mark
YA-URM Autonomy/ Competence, Social Support
기간: 6 month mark

Measured using the Healthcare Self-Determination survey

6 month mark
YA-URM Autonomy/ Competence, Social Support
기간: 9 month mark

Measured using the Healthcare Self-Determination survey

9 month mark
Hemoglobin A1c
기간: Baseline

Obtained by POC (in clinic) or laboratory (DCA Vantage)

Baseline
Hemoglobin A1c
기간: 3 month mark

Obtained by POC (in clinic) or laboratory (DCA Vantage)

3 month mark
Hemoglobin A1c
기간: 6 month mark

Obtained by POC (in clinic) or laboratory (DCA Vantage)

6 month mark
Hemoglobin A1c
기간: 9 month mark

Obtained by POC (in clinic) or laboratory (DCA Vantage)

9 month mark
Quality of Life (Diabetes Distress)
기간: Baseline

Validated survey: Type 1 Diabetes and Life Scale - Young Adult (T1DAL-YA)

Likert Scale: 1-5 (1= no, not at all true, 2=no, not very true, 3=sometimes true, sometimes not true, 4=yes, a little true, 5= yes, very true)

Baseline
Quality of Life (Diabetes Distress)
기간: Baseline

Validated surveys: Problem Areas in Diabetes (PAID)

The scores for each item are summed, then multiplied by 1.25 to generate a total score out of 100.

  • Total scores of 40 and above: severe diabetes distress
  • Individual items scored 3 or 4: moderate to severe distress to be discussed during the appointment following completion of the questionnaire.
Baseline
Quality of Life (Diabetes Distress)
기간: Baseline

Validated survey: Diabetes Self-Management Questionnaire (DSMQ)

Baseline
Quality of Life (Diabetes Distress)
기간: Baseline

Validated survey: Healthcare Climate Questionnaire (HCCQ)

Likert Scale (1-7) 1= strongly disagree ---- 7= strongly agree

Higher average scores represent a higher level of perceived autonomy support.

Baseline
Quality of Life (Diabetes Distress)
기간: 3 month follow-up

Validated survey: Type 1 Diabetes and Life Scale - Young Adult (T1DAL-YA)

Likert Scale: 1-5 (1= no, not at all true, 2=no, not very true, 3=sometimes true, sometimes not true, 4=yes, a little true, 5= yes, very true)

3 month follow-up
Quality of Life (Diabetes Distress)
기간: 3 month follow-up

Validated surveys: Problem Areas in Diabetes (PAID)

The scores for each item are summed, then multiplied by 1.25 to generate a total score out of 100.

  • Total scores of 40 and above: severe diabetes distress
  • Individual items scored 3 or 4: moderate to severe distress to be discussed during the appointment following completion of the questionnaire.
3 month follow-up
Quality of Life (Diabetes Distress)
기간: 3 month follow-up

Validated survey: Diabetes Self-Management Questionnaire (DSMQ)

3 month follow-up
Quality of Life (Diabetes Distress)
기간: 3 month follow-up

Validated survey: Healthcare Climate Questionnaire (HCCQ)

Likert Scale (1-7) 1= strongly disagree ---- 7= strongly agree

Higher average scores represent a higher level of perceived autonomy support.

3 month follow-up
Quality of Life (Diabetes Distress
기간: 6 month follow-up

Validated survey: Type 1 Diabetes and Life Scale - Young Adult (T1DAL-YA)

Likert Scale: 1-5 (1= no, not at all true, 2=no, not very true, 3=sometimes true, sometimes not true, 4=yes, a little true, 5= yes, very true)

6 month follow-up
Quality of Life (Diabetes Distress)
기간: 6 month follow-up

Validated surveys: Problem Areas in Diabetes (PAID)

The scores for each item are summed, then multiplied by 1.25 to generate a total score out of 100.

  • Total scores of 40 and above: severe diabetes distress
  • Individual items scored 3 or 4: moderate to severe distress to be discussed during the appointment following completion of the questionnaire.
6 month follow-up
Quality of Life (Diabetes Distress)
기간: 6 month follow-up

Validated survey: Diabetes Self-Management Questionnaire (DSMQ)

6 month follow-up
Quality of Life (Diabetes Distress)
기간: 6 month follow-up

Validated survey: Healthcare Climate Questionnaire (HCCQ)

Likert Scale (1-7) 1= strongly disagree ---- 7= strongly agree

Higher average scores represent a higher level of perceived autonomy support.

6 month follow-up

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 수석 연구원: Shivani Agarwal, MD, MPH, Albert Einstein College of Medicine

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

일반 간행물

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2022년 11월 7일

기본 완료 (실제)

2025년 9월 8일

연구 완료 (실제)

2025년 12월 8일

연구 등록 날짜

최초 제출

2021년 12월 16일

QC 기준을 충족하는 최초 제출

2022년 1월 26일

처음 게시됨 (실제)

2022년 1월 27일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 12일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 10월 20일

마지막으로 확인됨

2026년 10월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • 2021-13714
  • R01DK132302 (미국 NIH 보조금/계약)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다